Pharmacokinetics, quorum-sensing signal molecules and tryptophan-related metabolomics of the novel anti-virulence drug Fluorothiazinon in a Pseudomonas aeruginosa-induced pneumonia murine model-Reference-Cited by-同舟云学术

Pharmacokinetics, quorum-sensing signal molecules and tryptophan-related metabolomics of the novel anti-virulence drug Fluorothiazinon in a Pseudomonas aeruginosa-induced pneumonia murine model

Published:2023-11 Issue: Volume:236 Page:115739
ISSN:0731-7085
Container-title:Journal of Pharmaceutical and Biomedical Analysis
language:en
Short-container-title:Journal of Pharmaceutical and Biomedical Analysis

Author:

Savitskii Mark V.,Moskaleva Natalia E.,Brito Alex,Zigangirova Nailya A.,Soloveva Anna V.,Sheremet Anna B.,Bondareva Natalia E.,Lubenec Nadezhda L.,Kuznetsov Roman M.,Samoylov Viktor M.,Tagliaro Franco,Appolonova Svetlana A.

Funder

Ministry of Education and Science of the Russian Federation

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry

Reference35 articles.

1. Pseudomonas aeruginosa: an audacious pathogen with an adaptable arsenal of virulence factors;Jurado-Martín;IJMS,2021

2. Antivirulence compounds: a future direction to overcome antibiotic resistance?;Buroni;Future Microbiol.,2020

3. Understanding the mechanisms and drivers of antimicrobial resistance;Holmes;Lancet,2016

4. Possible drugs for the treatment of bacterial infections in the future: anti-virulence drugs;Ogawara;J. Antibiot.,2021

5. Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance;Dickey;Nat. Rev. Drug Discov.,2017

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Indazole–Quinolone Hybrids as Anti-Virulence Agents against Pseudomonas aeruginosa;Drugs and Drug Candidates;2024-07-19

2. Pharmacokinetics, tissue distribution, bioavailability and excretion of the anti-virulence drug Fluorothiazinon in rats and rabbits;The Journal of Antibiotics;2024-03-15

3. Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials;Expert Opinion on Investigational Drugs;2024-03-06